(CNS) Cohen & Steers - Ratings and Ratios
Real Estate, Preferred Securities, Infrastructure, Mutual Funds, Multi-Asset
CNS EPS (Earnings per Share)
CNS Revenue
Description: CNS Cohen & Steers August 03, 2025
Cohen & Steers Inc (NYSE:CNS) is a leading global investment manager specializing in real assets and alternative income. The firm provides asset management services to institutional investors, including pension funds, endowments, and foundations, through its subsidiaries. It offers a range of investment products, including equity, fixed income, multi-asset, and commodity portfolios, as well as hedge funds and mutual funds.
From a financial perspective, Cohen & Steers has demonstrated strong performance, with a Return on Equity (RoE) of 32.86%, indicating efficient use of shareholder capital. To further evaluate the companys performance, we can examine additional Key Performance Indicators (KPIs) such as Assets Under Management (AUM) growth, revenue diversification, and expense ratio. AUM growth is a critical metric for asset management companies, as it reflects their ability to attract and retain clients. Revenue diversification is also important, as it indicates the companys ability to generate revenue from multiple sources, reducing dependence on a single product or service.
Some other relevant KPIs for Cohen & Steers include its dividend yield, which can indicate the companys ability to distribute profits to shareholders, and its investment product performance relative to benchmarks, which can reflect the firms investment management capabilities. For example, if Cohen & Steers equity funds consistently outperform their respective benchmarks, it may indicate strong stock selection and portfolio management skills. Additionally, the companys expense ratio, which measures the total operating expenses as a percentage of AUM, can provide insight into its operational efficiency.
Overall, Cohen & Steers strong financial performance, diversified investment products, and global presence make it a significant player in the asset management industry. By examining relevant KPIs, investors can gain a more comprehensive understanding of the companys strengths and weaknesses, and make more informed investment decisions.
CNS Stock Overview
| Market Cap in USD | 3,647m |
| Sub-Industry | Asset Management & Custody Banks |
| IPO / Inception | 2004-08-13 |
CNS Stock Ratings
| Growth Rating | -14.5% |
| Fundamental | 63.6% |
| Dividend Rating | 65.9% |
| Return 12m vs S&P 500 | -40.7% |
| Analyst Rating | 4.0 of 5 |
CNS Dividends
| Dividend Yield 12m | 3.59% |
| Yield on Cost 5y | 4.97% |
| Annual Growth 5y | 10.90% |
| Payout Consistency | 85.5% |
| Payout Ratio | 63.8% |
CNS Growth Ratios
| Growth Correlation 3m | -71% |
| Growth Correlation 12m | -91.5% |
| Growth Correlation 5y | 36.7% |
| CAGR 5y | 8.45% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.22 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.56 |
| Sharpe Ratio 12m | -0.55 |
| Alpha | -53.98 |
| Beta | 1.354 |
| Volatility | 32.81% |
| Current Volume | 289.2k |
| Average Volume 20d | 305k |
| Stop Loss | 66.1 (-3.2%) |
| Signal | -0.45 |
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (167.0m TTM) > 0 and > 6% of Revenue (6% = 33.6m TTM) |
| FCFTA -0.16 (>2.0%) and ΔFCFTA -31.32pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 52.64% (prev 68.31%; Δ -15.67pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.15 (>3.0%) and CFO -116.1m <= Net Income 167.0m (YES >=105%, WARN >=100%) |
| Net Debt (46.2m) to EBITDA (226.6m) ratio: 0.20 <= 3.0 (WARN <= 3.5) |
| Current Ratio 24.33 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (51.6m) change vs 12m ago 1.58% (target <= -2.0% for YES) |
| Gross Margin 48.78% (prev 45.28%; Δ 3.50pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 72.90% (prev 60.79%; Δ 12.11pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -13.48 (EBITDA TTM 226.6m / Interest Expense TTM -16.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.34
| (A) 0.39 = (Total Current Assets 307.2m - Total Current Liabilities 12.6m) / Total Assets 751.0m |
| (B) -0.16 = Retained Earnings (Balance) -117.5m / Total Assets 751.0m |
| (C) 0.28 = EBIT TTM 215.8m / Avg Total Assets 767.5m |
| (D) -0.58 = Book Value of Equity -120.9m / Total Liabilities 208.7m |
| Total Rating: 3.34 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 63.55
| 1. Piotroski 4.0pt = -1.0 |
| 2. FCF Yield -3.44% = -1.72 |
| 3. FCF Margin -21.88% = -7.50 |
| 4. Debt/Equity 0.27 = 2.46 |
| 5. Debt/Ebitda 0.20 = 2.47 |
| 6. ROIC - WACC (= 21.12)% = 12.50 |
| 7. RoE 32.76% = 2.50 |
| 8. Rev. Trend 33.44% = 2.51 |
| 9. EPS Trend 26.51% = 1.33 |
What is the price of CNS shares?
Over the past week, the price has changed by -4.46%, over one month by +4.93%, over three months by -6.69% and over the past year by -28.19%.
Is Cohen & Steers a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CNS is around 57.62 USD . This means that CNS is currently overvalued and has a potential downside of -15.66%.
Is CNS a buy, sell or hold?
- Strong Buy: 1
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CNS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 74.3 | 8.8% |
| Analysts Target Price | 74.3 | 8.8% |
| ValueRay Target Price | 65.5 | -4.2% |
CNS Fundamental Data Overview October 30, 2025
P/E Trailing = 22.4119
P/E Forward = 18.6567
P/S = 6.6053
P/B = 6.2827
P/EG = 0.8007
Beta = 1.354
Revenue TTM = 559.5m USD
EBIT TTM = 215.8m USD
EBITDA TTM = 226.6m USD
Long Term Debt = 141.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 14.0m USD (from shortTermDebt, last fiscal year)
Debt = 141.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 46.2m USD (from netDebt column, last quarter)
Enterprise Value = 3.56b USD (3.65b + Debt 141.6m - CCE 230.1m)
Interest Coverage Ratio = -13.48 (Ebit TTM 215.8m / Interest Expense TTM -16.0m)
FCF Yield = -3.44% (FCF TTM -122.4m / Enterprise Value 3.56b)
FCF Margin = -21.88% (FCF TTM -122.4m / Revenue TTM 559.5m)
Net Margin = 29.84% (Net Income TTM 167.0m / Revenue TTM 559.5m)
Gross Margin = 48.78% ((Revenue TTM 559.5m - Cost of Revenue TTM 286.6m) / Revenue TTM)
Gross Margin QoQ = 48.12% (prev 48.13%)
Tobins Q-Ratio = 4.74 (Enterprise Value 3.56b / Total Assets 751.0m)
Interest Expense / Debt = 0.36% (Interest Expense 503.0k / Debt 141.6m)
Taxrate = 25.06% (13.9m / 55.6m)
NOPAT = 161.7m (EBIT 215.8m * (1 - 25.06%))
Current Ratio = 24.33 (Total Current Assets 307.2m / Total Current Liabilities 12.6m)
Debt / Equity = 0.27 (Debt 141.6m / totalStockholderEquity, last quarter 528.5m)
Debt / EBITDA = 0.20 (Net Debt 46.2m / EBITDA 226.6m)
Debt / FCF = -0.38 (negative FCF - burning cash) (Net Debt 46.2m / FCF TTM -122.4m)
Total Stockholder Equity = 509.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 22.23% (Net Income 167.0m / Total Assets 751.0m)
RoE = 32.76% (Net Income TTM 167.0m / Total Stockholder Equity 509.7m)
RoCE = 33.13% (EBIT 215.8m / Capital Employed (Equity 509.7m + L.T.Debt 141.6m))
RoIC = 31.72% (NOPAT 161.7m / Invested Capital 509.7m)
WACC = 10.60% (E(3.65b)/V(3.79b) * Re(11.0%) + D(141.6m)/V(3.79b) * Rd(0.36%) * (1-Tc(0.25)))
Discount Rate = 11.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.26%
Fair Price DCF = unknown (Cash Flow -122.4m)
EPS Correlation: 26.51 | EPS CAGR: 0.91% | SUE: 0.75 | # QB: 0
Revenue Correlation: 33.44 | Revenue CAGR: 0.46% | SUE: 0.11 | # QB: 0
Additional Sources for CNS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle